利用新冠疫苗过敏评估同步开展药物过敏去标签:有效性与对生活质量的影响
研究招募2021至2022年香港因新冠疫苗评估就诊且被标注药物过敏的个体,分析同步药物过敏去标签的有效性及健康相关生活质量变化。652人中1456个药物过敏标签,228人接受药物过敏检查,223人(97.8%)去标签成功,移除317个(21.8%)错误标签。亚组分析显示去标签后健康相关生活质量改善(DrHy-Q 45.0 vs 33.3,p < 0.001)。
要点
- 新冠疫苗过敏评估服务中同步药物过敏去标签成功率高(97.8%)。
- 去标签后健康相关生活质量改善(DrHy-Q 45.0 vs 33.3,p < 0.001)。
- 99.4%个体安全接种新冠疫苗,接种剂次增加带来更好保护。
核心结论
- 评估新冠疫苗过敏的服务不仅使被标注药物过敏的个体安全接种疫苗,还扩大了公众获得药物过敏去标签服务的机会。
研究设计与样本
- 研究招募2021至2022年香港因新冠疫苗评估就诊且被标注药物过敏的个体,分析人口学、合并症、药物过敏标签、新冠疫苗接种与感染结局及同步去标签率,并在亚组中测量评估前后健康相关生活质量。
主要发现
- 652人中识别1456个药物过敏标签,抗感染药物最常见(606个,41.6%),其中β-内酰胺类抗生素占55.1%(334个)。
- 99.4%个体安全接种新冠疫苗,接种剂次增加带来更好保护。
- 228人(35.0%)接受药物过敏检查,223人(97.8%)同步去标签成功,移除317个(21.8%)错误标签,其中173个(51.8%)为β-内酰胺类。
- 亚组分析显示去标签后系列健康相关生活质量改善(DrHy-Q 45.0 vs 33.3,p < 0.001)。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Concerns of potential drug/vaccine-associated allergies significantly impact vaccine safety and hesitancy. Delabelling of incorrect drug allergy in the general public was previously impeded by limited access to allergist services, especially among less frequent healthcare utilisers in the community. COVID-19 vaccine allergy evaluation services have enabled individuals (mis)labelled with allergies to receive vaccinations safely and have provided opportunities to expand drug allergy delabeling access. We investigated the effectiveness of this coincident drug allergy delabelling and its impact on health-related quality of life (HRQoL). METHODS: We recruited individuals labelled with drug allergies attending for COVID-19 vaccine evaluation in Hong Kong between 2021 and 2022. Demographics, comorbidities, drug allergy labels, COVID-19 vaccination and infection outcomes, as well as coincident delabelling rates were analysed. HRQoL was measured before and after evaluation in a subgroup of individuals. RESULTS: Among 652 individuals, 1456 drug allergy labels were identified, with anti-infectives being the most common (606, 41.6 %). Beta-lactam antibiotics accounted for 55.1 % (334). Almost all individuals (99.4 %) safely proceeded with COVID-19 vaccinations, with an increased number of doses conferring better protection. 228 (35.0 %) individuals underwent drug allergy investigations, with coincident drug allergy delabelling successful in 223 (97.8 %), removing 317 (21.8 %) incorrect labels, of which 173 (51.8 %) were beta-lactams. Subgroup analysis showed improved serial health-related quality of life following delabelling (DrHy-Q 45.0 vs 33.3, p < 0.001). CONCLUSION: Services evaluating COVID-19 vaccine allergies have not only empowered individuals labelled with drug allergy to receive vaccinations safely, but have also enhanced access to drug allergy delabeling services for the general public.
引用
- Kan AKC, Mak HWF, Chiang V, et al. Leveraging COVID-19 vaccine allergy evaluations with coincident drug allergy delabelling: Effectiveness and impact on quality of life. Vaccine. 2025. PMID: 39914252. doi:10.1016/j.vaccine.2025.126849
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。